Market Overview

Mizuho Securities USA Sees Solid Underlying Business Trends For CVS Caremark

Share:

In a report published Monday, Mizuho Securities USA analyst Ann Hynes reiterated a Buy rating and $81.00 price target on CVS Caremark (NYSE: CVS).

In the report, Mizuho Securities USA noted, “We reiterate our Buy rating and $81 price target after a solid 1Q. Upside in the PBM helped offset weakness in retail driven by severe winter weather and a soft flu season. Even including the weather and tough flu comparisons, operating profit trends remain robust with y/y growth and margin expansion. We believe CVS is well positioned to capture share across both operating segments through continued solid execution, and we think earnings visibility is high.”

CVS Caremark closed on Friday at $73.86.

Latest Ratings for CVS

DateFirmActionFromTo
Dec 2019ReiteratesStrong Buy
Nov 2019MaintainsOverweight
Nov 2019MaintainsBuy

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Ann Hynes Mizuho Securities USAAnalyst Color Reiteration Analyst Ratings

 

Related Articles (CVS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
REALDA DavidsonInitiates Coverage On22.0
RVLVDA DavidsonInitiates Coverage On19.0
SFIXDA DavidsonInitiates Coverage On27.0
CONNKeyBancDowngrades
PENNJP MorganMaintains29.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Benzinga's Top #PreMarket Losers

UPDATE: MLV & Co Initiates Coverage On pSivida On Multiple Positive Factors